Navigation Links
The Need for Safe and Affordable Biopharmaceuticals Drives the Development of the European Biosimilars Market, Says Frost & Sullivan
Date:3/18/2009

LONDON, March 18 /PRNewswire/ -- Despite the initial regulatory hiccups, the number of biosimilars in the European market is set to increase gradually. The patent expiry of key biopharmaceuticals has opened up numerous lucrative market opportunities, while driving the development of biosimilars. In addition, payers' perception of biosimilars, as viable alternatives to originator drugs due to their safety, efficacy and affordability, will further bolster market prospects.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

"Patent expiries of some top selling biopharmaceuticals have resulted in a massive market opportunity for biosimilar manufacturers," notes Frost & Sullivan Senior Research Analyst Sumanth Kambhammettu. "Product classes such as erythropoietins, insulin and analogs, granulocyte colony-stimulating factors, human growth hormones and interferons, which have all lost patent protection, had a collective market size of approximately $34.04 billion in 2007."

If you are interested in a virtual brochure for the latest analysis from Frost & Sullivan (http://www.pharma.frost.com) titled, European Biosimilars Market Outlook, which provides manufacturers, end users and other industry participants with an overview of the study, send an e-mail to Katja Feick, Corporate Communications, at katja.feick@frost.com. Please include your full name, company name, title, telephone number, company e-mail address, company website, city, state and country. Upon receipt of the above information, an overview will be sent to you by e-mail.

Expensive biopharmaceuticals are used primarily for critical diseases like cancer and diabetes, whose incidence is increasing due to Europe's ageing population. Subsequently, the patent expiries of key product classes and an increasing emphasis on cost containment are motivating governments to switch to affordable alternatives. Thus, there exists tremendous growth opportunity for biosimilar manufacturers.

However, the development of biosimilars is riddled with complexities, ranging from R&D and manufacturing to marketing. Their development remains one of the most expensive propositions in the pharmaceutical industry. In addition, meeting the stringent regulatory norms set by the European Medicines Agency (EMEA) will be an arduous exercise.

The current average cost of bringing a biosimilar to market is around $100-$200 million, in addition to a development period ranging from eight to ten years. This is approximately equivalent to the same for a biopharmaceutical product. Marketing presents another key challenge as, typically, there is initial resistance from the physician community.

"The most significant challenge, however, will be in proving similarity with the reference product as per the EMEA standards," adds Kambhammettu. "This is because the entire process involves large-scale clinical trials as well as the documentation and submission of immense volumes of data."

Pricing will be a key factor to recover the high level of investment that is required to develop and manufacture biosimilars. In addition, marketing strategies will have to be very different from generic drugs.

"While pricing a biosimilar, manufacturers must assess various factors such as the nature of the market, product class, level of competition and reimbursement structure," advises Kambhammettu. "As current biosimilars are marketed in the hospital sector, manufacturers must focus their marketing efforts on specialists to increase the probability of success. Moreover, they must make efforts towards advancing physician awareness by disseminating data pertaining to long-term safety and efficacy of biosimilars."

European Biosimilars Market Outlook is part of the Pharmaceuticals & Biotechnology Growth Partnership Services programme, which also includes research in the following markets: Drug Approval Process in Europe, Opportunities in the CRO Market - Phase 0, European Vaccines Market, European Biosimilars Market, European Human Growth Hormones Market, European Therapeutic Monoclonal Antibody Market, European Drug Delivery Market, and European Lung Cancer Therapeutics Market. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.

Frost & Sullivan has expanded its flagship Global Congress on Corporate Growth - GIL Global - into several major cities around the world including London. For the first time ever in Europe, Frost & Sullivan will be hosting the Growth, Innovation and Leadership Congress 'GIL 2009: Europe' on 19-20 May, at the Sofitel St James in London. GIL Global is the industry's only event designed to support senior executives in their efforts to achieve sustainable, top-line growth. To register, obtain a programme agenda, explore sponsorship opportunities, or attend as a member of the media for GIL 2009: Europe, please contact Katja Feick, Corporate Communications Europe, at katja.feick@frost.com. One-on-One interviews with Frost & Sullivan senior growth consultants are also being scheduled. For more information you can also visit http://www.frost.com/gilglobal

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership(TM) empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan's Growth Partnership Services, visit http://www.frost.com.

European Biosimilars Market Outlook

M238

    Contact:
    Katja Feick
    Corporate Communications
    P: +49 (0) 69 7703343
    E: katja.feick@frost.com

http://www.frost.com/


'/>"/>
SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BIOLOCK(TM) USA Launches Affordable Fingerprint door Locks for Homes and Offices
2. DNA 11, Creators of DNA Art, Introduces a More Affordable Line of Custom Portraits for this Year's Gift Giving Season
3. ZhenSpa.com provides Spa Enthusiasts Affordable Alternatives for Expensive Spa Treatments
4. Secretropin(R) - Effective, Preferable, Affordable as an Alternative to Injectable Growth Hormone - Gains Momentum
5. Biogenerics Legislation Provides Critical Pathway to Affordable Access for Patients with Chronic and Complex Conditions
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
10. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
11. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... and LONDON , May 23, 2016 ... Frontage Boost Efficiency by 40% - Frontage Implement a ... Frontage Enforce Quality, Compliance and Traceability Within the Bioanalytical lab ... in the United States and ... be deployed across its laboratory facilities. In addition to serving as ...
(Date:5/23/2016)... ... May 23, 2016 , ... ... focused on molecular nanotechnology, announced the winners for the 2015 Foresight Institute Feynman ... Feynman, are given in two categories, one for experiment and the other for ...
(Date:5/20/2016)... San Diego, CA (PRWEB) , ... May 20, 2016 , ... ... announce that 10 of its most experienced veterinary clients have treated over 100 of ... this cutting edge technology to provide the highest level of care for their patients. ...
(Date:5/20/2016)... Raleigh, NC (PRWEB) , ... May 20, 2016 , ... ... cells, suggesting that it may offer a new way to treat the disease. Surviving ... read it now. , Scientists from several Korean institutions based their mesothelioma study ...
Breaking Biology Technology:
(Date:4/26/2016)... BANGALORE, India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a ... ), and Onegini today announced a partnership to ... banking solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... banks to provide their customers enhanced security to ...
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys has ... CEO, Barrett Bready , M.D., who returned to ... the original technical leadership team, including Chief Technology Officer, ... Product Development, Steve Nurnberg and Vice President of Software ... the company. Dr. Bready served as CEO ...
Breaking Biology News(10 mins):